Cadent Therapeutics displays its lead asset’s testing progress, with new medical boss named
October 17, 2019Cadent Therapeutics has named Dawn Wilson appointed as Vice President, Clinical Operations, as it releases the data from Phase 2 study with lead asset in movement disorders, CAD-1883, which shows signal finding in Proof of Concept (POC) study in essential tremor.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, announced the appointments of Christopher Kenney, M.D. as Chief Medical Officer and Dawn Wilson as Vice President of Clinical Operations. Cadent also provided a clinical and pipeline progress update.
“I am delighted to welcome Chris as our Chief Medical Officer,” said Jodie Morrison, Chief Executive Officer of Cadent. “Chris brings over two decades of drug development expertise, including a deep focus in movement disorders, at a critical time for the company. His experience steering the development of drugs throughout his career will be invaluable as we advance into multiple Phase 2 clinical trials in 2020. Together with Dawn Wilson, our newly appointed Vice President of Clinical Operations, we are now well positioned to move Cadent’s promising pipeline forward. I look forward to their contributions as we seek to deliver on our commitment to improve the lives of patients with movement, mood, and cognitive disorders.”
“I am excited to be joining Cadent at this juncture, and I am impressed by the progress the team has made thus far on advancing its programs through the clinic,” said Dr. Kenney, Chief Medical Officer of Cadent. “The results of the first POC study with CAD-1883 from the movement disorders portfolio are encouraging. The safety profile and activity signal observed in the Phase 2 essential tremor trial validate Cadent’s approach to clinical designs for movement disorder research. I am thrilled to lead these important programs and believe they represent significant potential for new treatment options for patients in need.”